You are here
MolecularMD is acquired by ICON
PORTLAND, Ore. and CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- MolecularMD Corporation, a molecular diagnostic specialty laboratory that enables the development and commercialisation of precision medicines in oncology, announced today that it has been acquired by ICON plc (NASDAQ: ICLR). MolecularMD’s extensive scientific and clinical biomarker experience expands ICON’s capabilities in molecular diagnostic testing and also adds expanded testing platforms, including next-generation sequencing and immunohistochemistry, to ICON’s laboratory service offering. MolecularMD’s specialty central laboratory offering and associated client base extends ICON’s reach into the support of precision medicine programs across all phases of drug – diagnostic co-development.
Thursday, February 21, 2019 - 10:00